Rhythm Pharmaceuticals

Looking to win over some skeptical analysts, Rhythm beats the drum on interim data in PhII basket study for additional indications
Looking to win over some skeptical analysts, Rhythm beats the drum on interim data in PhII basket study for additional indications
Endpoints
Rhythm Pharmaceuticals
clinical trials
setmelanotide
obesity
Flag link:
Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many
Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many
Endpoints
Rhythm Pharmaceuticals
setmelanotide
obesity
clinical trials
Flag link:
FDA gives Rhythm the green light for setmelanotide, a drug aimed at reducing obesity in certain genetic disorders
FDA gives Rhythm the green light for setmelanotide, a drug aimed at reducing obesity in certain genetic disorders
Endpoints
Rhythm Pharmaceuticals
setmelanotide
obesity
FDA
Flag link:
The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates
The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates
Yahoo/Benzinga
vaccines
COVID-19
Roche
ReVance
Moderna Therapeutics
FDA
Rhythm Pharmaceuticals
Liquidia
Flag link:
Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO
Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO
Xconomy
Rhythm Pharmaceuticals
FDA
setmelanotide
Flag link:
Rhythm Pharma CEO Gottesdeiner to Step Down After FDA Filing
Rhythm Pharma CEO Gottesdeiner to Step Down After FDA Filing
Xconomy
Rhythm Pharmaceuticals
Keith Gottesdiener
Flag link:
The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
Rhythm’s genetic obesity drug hits primary endpoint in phase 3
Rhythm’s genetic obesity drug hits primary endpoint in phase 3
Fierce Biotech
Rhythm Pharmaceuticals
genetic obesity
clinical trials
setmelanotide
Flag link:
Building up its rare obesity pipeline, Rhythm Pharma to raise $150M
Building up its rare obesity pipeline, Rhythm Pharma to raise $150M
Endpoints
Rhythm Pharmaceuticals
R&D
obesity
Flag link:
Successful IPO for Rhythm Pharmaceuticals: +52%
Successful IPO for Rhythm Pharmaceuticals: +52%
GoinPharma
IPOs
Rhythm Pharmaceuticals
Flag link:
Rhythm Pharma strikes a chord with oversubscribed $120M IPO
Rhythm Pharma strikes a chord with oversubscribed $120M IPO
Fierce Biotech
Rhythm Pharmaceuticals
IPOs
Flag link:
Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
Endpoints
Rhythm Pharmaceuticals
IPOs
obesity
rare disease
Flag link:
Pfizer, OrbiMed back $40M Rhythm round for rare genetic disease R&D
Pfizer, OrbiMed back $40M Rhythm round for rare genetic disease R&D
Fierce Biotech
Pfizer
OrbiMed
Rhythm Pharmaceuticals
Prader-Willi Syndrome
Flag link:
Two new biotech IPOs help set the stage for the fall parade
Two new biotech IPOs help set the stage for the fall parade
Fierce Biotech
IPOs
Rhythm Pharmaceuticals
Dermira
Flag link:
Rhythm Pharmaceuticals lands $11M tranche to advance its treatment of GI disorders
Rhythm Pharmaceuticals lands $11M tranche to advance its treatment of GI disorders
bizjournals
Rhythm Pharmaceuticals
gastroparesis
diabetes
obesity
Flag link:
Rise in obesity makes VCs hungry for startups
Rise in obesity makes VCs hungry for startups
Reuters
venture capital
obesity
Rhythm Pharmaceuticals
Elixir Medical
Flag link: